\
&
Contact us
\
&
Contact us
Select your Horizon Europe programme part
The European Commission publishes the draft work programmes on the comitology register. This tool browses the register and attempts to detect all available drafts and marks it with Draft Work Programme, allowing you to easily navigate the different documents.
This is an automatic tool, so mistakes are possible. If you notice something or have feedback to improve this tool, don't hesitate to contact us at info@ncpflanders.be.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
